Payment overview · 2025
General Payments
$273.92
14 reported records · 10 companies
Healthcare provider profile · identity verified
Jeffery Thomas Horton, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CHIPLEY, FL · NPI 1396997193
Verified facts
What the public records show
CMS Open Payments records show Jeffery Thomas Horton, ARNP received $273.92 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.26 | 20.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.60 | 14.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.56 | 11.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $29.85 | 10.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.44 | 10.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.75 | 7.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.24 | 7.0% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.73 | 6.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.87 | 5.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.62 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $273.92 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.26 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.60 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.60 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.56 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $29.85 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.44 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 344 | 67 |
| Omeprazole | Omeprazole | 336 | 76 |
| Gabapentin | Gabapentin | 327 | 70 |
| Lisinopril | Lisinopril | 315 | 58 |
| Losartan Potassium | Losartan Potassium | 288 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 276 | 51 |
| Trazodone Hcl | Trazodone Hcl | 272 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 57 |
| Montelukast Sodium | Montelukast Sodium | 263 | 57 |
| Meloxicam | Meloxicam | 243 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 221 | 49 |
| Azithromycin | Azithromycin | 219 | 114 |
| Simvastatin | Simvastatin | 199 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 34 |
| Metformin Hcl | Metformin Hcl | 164 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 158 | 30 |
| Methylprednisolone | Methylprednisolone | 157 | 104 |
| Alprazolam | Alprazolam | 150 | 26 |
| Carvedilol | Carvedilol | 143 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 142 | 35 |
| Clonazepam | Clonazepam | 141 | 22 |
| Potassium Chloride | Potassium Chloride | 139 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 138 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 28 |
| Donepezil Hcl | Donepezil Hcl | 135 | 29 |
| Furosemide | Furosemide | 135 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 30 |
| Bupropion Xl | Bupropion Hcl | 106 | 15 |
| Pregabalin | Pregabalin | 103 | 15 |
| Mounjaro | Tirzepatide | 99 | 17 |
| Sertraline Hcl | Sertraline Hcl | 99 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 97 | 24 |
| Tramadol Hcl | Tramadol Hcl | 93 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 30 |
| Buspirone Hcl | Buspirone Hcl | 88 | 20 |
| Fluconazole | Fluconazole | 87 | 44 |
| Allopurinol | Allopurinol | 81 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 15 |
| Ibuprofen | Ibuprofen | 76 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 73 | 43 |
| Levofloxacin | Levofloxacin | 71 | 41 |
| Promethazine Hcl | Promethazine Hcl | 66 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 44 |
| Cephalexin | Cephalexin | 64 | 46 |
| Famotidine | Famotidine | 63 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 62 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 12 |
| Sucralfate | Sucralfate | 59 | 20 |
| Ozempic | Semaglutide | 57 | 11 |
| Linzess | Linaclotide | 56 | 11 |
| Ondansetron Odt | Ondansetron | 56 | 14 |
| Glipizide | Glipizide | 55 | 11 |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 52 | suppressed |
| Temazepam | Temazepam | 52 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 51 | 14 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 48 | 13 |
| Clonidine Hcl | Clonidine Hcl | 48 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 11 |
| Celecoxib | Celecoxib | 47 | 11 |
| Primidone | Primidone | 46 | 12 |
| Methocarbamol | Methocarbamol | 45 | 11 |
| Prednisone | Prednisone | 45 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Ezetimibe | Ezetimibe | 44 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | 13 |
| Glipizide Er | Glipizide | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 13 |
| Eliquis | Apixaban | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Premarin | Estrogens, Conjugated | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 18 |
| Estradiol | Estradiol | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 14 |
| Bumetanide | Bumetanide | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Nystatin | Nystatin | 20 | 14 |
| Valsartan | Valsartan | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Klor-Con 8 | Potassium Chloride | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 15 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Caplyta | Lumateperone Tosylate | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $273.92 · 14 records | ABBVIE INC. | Auvelity, Cologuard Collection Kit, FARXIGA, NURTEC ODT, Ozempic, Qelbree, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, ZAVZPRET, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error